Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Vanguard International High Dividend Yield ETF trades at $102. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Vanguard International High Dividend Yield ETF pays none, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | VYMI | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $812.27 | $101.60 |
52-Week Low | $545.46 | $79.95 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
VYMI trades at $100.23, down 0.65% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF offers international high dividend yield exposure with over 1,500 stocks and has delivered 10.8% annualized returns over 10 years. Recent institutional buying by D.A. Davidson & CO. increased their position by 265.6% during the latest quarter.
VYMI presents a compelling international diversification opportunity with strong dividend growth potential, though currency fluctuations and global economic conditions pose risks. The ETF's low 0.07% expense ratio and broad diversification across developed and emerging markets provide defensive characteristics in uncertain market environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
